Immunochemotherapy in primary central nervous system lymphoma with rituximab, HD-MTX, HD Ara-C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide,and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide - NLG PCNS
Active, not recruiting
- Conditions
- First line treatment of primary central nervous system lymphomaMedDRA version: 9.1Level: LLTClassification code 10036685Term: Primary central nervous system lymphoma
- Registration Number
- EUCTR2006-004772-12-FI
- Lead Sponsor
- ordic lymphoma group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Pathologically verified primary central nervous system lymphoma
No prior treatment
Written informed consent
No serious comorbid illnesses
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Pregnancy or lactation
Previous malignancy
Known hypersensitivity to study drug
Serious comorbid illnesses
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method